Completed PHASE1 INTERVENTIONAL 6-arm NCT01489020

Subcutaneous Immunotherapy in Patients Sensitized to Dermatophagoides Pteronyssinus (DPT)

Multicentre Phase I Randomized Double Blind Placebo Controlled Study of Subcutaneous Immunotherapy in Subjects With Allergic Rhinoconjunctivitis ± Asthma Sensitised to Dermatophagoides Pteronyssinus.

Sponsor: Roxall Medicina España S.A

Conditions Allergic Rhinoconjunctivitis

Interventions Subcutaneous depot placebo subcutaneous immunotherapy with DPT extract

Updated 8 times since 2017 Last updated: Jan 29, 2019 Started: Jan 31, 2011 Primary completion: Jul 31, 2011 Completion: Aug 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Allergic Rhinoconjunctivitis and is currently completed. Roxall Medicina España S.A leads this study, which shows 8 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Dec 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Dec 2021 [monthly]

Completed PHASE1
Jun 2019 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jun 2018 — Jun 2019 [monthly]

Completed PHASE1
Jun 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Jun 2017 [monthly]

Completed PHASE1

First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Roxall Medicina España S.A

Data source: Roxall Medicina España S.A

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bilbao, Spain
• Valencia, Spain